Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
10-year outcome trajectories of people with mental illness and their families who receive services from multidisciplinary case management and outreach teams: protocol of a multisite longitudinal study.
Yamaguchi S, Usui K, Iwanaga M, Kawaguchi T, Hada A, Yoshida K, Nishio M, Yanata H, Watanabe M, Taniguchi K, Aoki H, Hisajima Y, Sato S, Fujii C. Yamaguchi S, et al. Among authors: usui k. BMJ Open. 2024 Aug 31;14(8):e085532. doi: 10.1136/bmjopen-2024-085532. BMJ Open. 2024. PMID: 39298130 Free PMC article.
Comparative Analysis of Independent Reviewer-Rated and Self-Rated Fidelity Scores in Individual Placement and Support Programs: Repeated Cross-Sectional Surveys.
Yamaguchi S, Koike J, Igarashi M, Kawaguchi T, Shiozawa T, Usui K, Iwanaga M, Matsunaga A, Yoshida K, Sato S, Fujii C. Yamaguchi S, et al. Among authors: usui k. Adm Policy Ment Health. 2024 Sep 25. doi: 10.1007/s10488-024-01413-y. Online ahead of print. Adm Policy Ment Health. 2024. PMID: 39322777
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.
Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. Hirata T, et al. Among authors: usui k. Jpn J Clin Oncol. 2024 Dec 20:hyae176. doi: 10.1093/jjco/hyae176. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39703183
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.
Sonehara K, Tateishi K, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Sonehara K, et al. Among authors: usui k. Thorac Cancer. 2024 Dec 7. doi: 10.1111/1759-7714.15507. Online ahead of print. Thorac Cancer. 2024. PMID: 39644181 Free article.
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Karayama M, Suda T, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Karayama M, et al. Among authors: usui k. Lung Cancer. 2024 Dec;198:108037. doi: 10.1016/j.lungcan.2024.108037. Epub 2024 Nov 26. Lung Cancer. 2024. PMID: 39602849
689 results